LCTX · Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics' Q1 2026 results reflect ongoing investment in its allogeneic cell therapy pipeline, with revenues increasing modestly to $1.7 million primarily from the new research collaboration with William Demant Invest A/S (WDI) for the ReSonance hearing loss program. Operating expenses rose 16% to $9.3 million, driven by higher R&D spending across OPC1 ($0.3M increase), ReSonance ($0.2M), and preclinical programs ($0.7M), alongside slight G&A growth from personnel costs. Despite a wider operating loss of $7.6 million, other income of $2.8 million from exchange rate gains helped narrow the net loss to $4.8 million or $0.03 per diluted share. CEO Brian Culley highlighted pipeline advancements including the launch of COR1 for corneal endothelial diseases, first milestone in AlloSCOPE 5D manufacturing for potential Type 1 Diabetes applications, and progress in the OPC1 DOSED study for spinal cord injury. Positive 3-year Phase 1/2a data for RG6501 (OpRegen) in geographic atrophy was featured at a summit, supporting ongoing Roche/Genentech collaboration. The $53.4 million cash position provides runway into Q2 2028, aligning with disciplined spending and partner support to advance seven cell therapy programs.